Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study
Heesun J. Rogers,
James W. Vardiman,
John Anastasi,
Gordana Raca,
Natasha M. Savage,
Athena M. Cherry,
Daniel Arber,
Erika Moore,
Jennifer JD. Morrissette,
Adam Bagg,
Yen-Chun Liu,
Susan Mathew,
Attilio Orazi,
Pei Lin,
Sa A. Wang,
Carlos E. Bueso-Ramos,
Kathryn Foucar,
Robert P. Hasserjian,
Ramon V. Tiu,
Matthew Karafa,
Eric D. Hsi
Affiliations
Heesun J. Rogers
Department of Clinical Pathology, Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, OH
James W. Vardiman
Department of Pathology, University of Chicago, IL
John Anastasi
Department of Pathology, University of Chicago, IL
Gordana Raca
Department of Medicine, University of Chicago, IL
Natasha M. Savage
Department of Pathology, Stanford University, CA
Athena M. Cherry
Department of Pathology, Stanford University, CA
Daniel Arber
Department of Pathology, Stanford University, CA
Erika Moore
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
Jennifer JD. Morrissette
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
Adam Bagg
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
Yen-Chun Liu
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY
Susan Mathew
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY
Attilio Orazi
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY
Pei Lin
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Sa A. Wang
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Carlos E. Bueso-Ramos
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Kathryn Foucar
Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM
Robert P. Hasserjian
Department of Pathology, Massachusetts General Hospital, Boston, MA
Ramon V. Tiu
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, OH
Matthew Karafa
Department of Quantitative Health Sciences, Cleveland Clinic, OH, USA
Eric D. Hsi
Department of Clinical Pathology, Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, OH
Acute myeloid leukemia and myelodysplastic syndrome with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) have a poor prognosis. Indeed, the inv(3)(q21q26.2)/t(3;3)(q21;q26.2) has been recognized as a poor risk karyotype in the revised International Prognostic Scoring System. However, inv(3)(q21q26.2)/t(3;3)(q21;q26.2) is not among the cytogenetic abnormalities pathognomonic for diagnosis of acute myeloid leukemia irrespective of blast percentage in the 2008 WHO classification. This multicenter study evaluated the clinico-pathological features of acute myeloid leukemia/myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and applied the revised International Prognostic Scoring System to myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). A total of 103 inv(3)(q21q26.2)/t(3;3)(q21;q26.2) patients were reviewed and had a median bone marrow blast count of 4% in myelodysplastic syndrome (n=40) and 52% in acute myeloid leukemia (n=63) (P
